Studying tumor DNA in HER2-low advanced breast cancer
Part of Cancer clinical trials.
This trial looks at tumor DNA in the blood of people with a certain type of advanced breast cancer called HER2-low. The goal is to learn more about this cancer and how it changes over time, which may help guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HER2-low breast cancer, meaning your cancer cells have a low amount of a protein called HER2 (scored as IHC 1+ or IHC 2+ but not amplified).
- Your breast cancer has spread or is advanced, and you have not started treatment for this advanced stage yet.
- You must be willing to give blood samples for testing.
- You must be able to come in for follow-up visits with your study team.
- You must sign a consent form to confirm you understand and agree to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a more precise way to measure HER2 levels in breast cancer tissue. It may help identify patients whose cancer is HER2-low or HER2-zero, so they can get more targeted treatment.
This trial looks at tumor cells in the blood of women with breast cancer to understand them better. It may help doctors learn more about how the disease spreads.
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
This study looks for tiny traces of cancer after treatment by testing blood for “ctDNA,” which is leftover cancer DNA. It includes people with HER2-positive early breast cancer who are getting chemotherapy before surgery to see if this blood test can detect signs of remaining disease.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This trial tests whether using a blood test for tumor DNA can help doctors decide the best treatment for people with HER2-negative breast cancer that has spread. It focuses on a type of therapy called an antibody-drug conjugate (ADC) and aims to personalize your care.
Hear when a new Advanced/Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.